PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact

PD 1 & PD L1 Inhibitors .pdf

Original filename: PD-1 & PD-L1 Inhibitors.pdf

This PDF 1.5 document has been generated by Microsoft® PowerPoint® 2016 / www.ilovepdf.com, and has been sent on pdf-archive.com on 05/02/2018 at 09:26, from IP address 103.97.x.x. The current document download page has been viewed 255 times.
File size: 772 KB (6 pages).
Privacy: public file

Download original PDF file

Document preview

Global Programmed Death-1 (PD-1) &
Programmed Death Ligand-1 (PD-L1) Inhibitors
Market to Witness 23.4% CAGR During 2017 – 2025



PD-1 & PD-L1 Inhibitors

Positive Clinical Results Supporting the Pipeline Growth
The global programmed death-1 (PD-1) and programmed death ligand-1
(PD-L1) inhibitors market is valued at an estimated $4,926.4 million in 2016,
and it is expected to grow at a CAGR of 23.4% during 2017 - 2025. The
growth of the global market is largely driven by the increased investment
and funding, strong pipeline, and improved safety and efficacy.
Explore Report with Detailed TOC at:

PD-1 & PD-L1 Inhibitors

Some of the other factors driving the growth of the global market include
technological advancements and innovations, and high prevalence of
cancer. Less number of competitors and expected launch of Phase III drug
candidates will create ample growth opportunities for the global market.
However, high cost of research and therapy, and stringent and time
consuming regulatory process are the key barriers for the growth of the
global market.

PD-1 and PD-L1 inhibitors are highly growing immunotherapies that are
being used in oncology therapy area. The pipeline of PD-1 and PD-L1
inhibitors is enriched with 47 drugs and there are approximately 245 active
clinical studies. There are many drugs in early stage of pipeline; thus,
making PD1 and PDL1 inhibitors market very lucrative.

PD-1 & PD-L1 Inhibitors

The information and data in the publication “Global Programmed Death-1 (PD-1)
& Programmed Death Ligand-1 (PD-L1) Inhibitors Pipeline Analysis, Market Size,
Share, Development, Growth and Demand Forecast to 2025” represents the
research and analysis of data from various primary and secondary sources. An
amalgamation of bottom-up and top-down has been used to calculate the
market size. P&S Market Research analysts and consultants interacted with
leading companies of the concerned domain to substantiate every value of data
presented in the report. The company bases its primary research on discussions
with prominent professionals and analysts in the industry, which is followed by
informed and detailed, online and offline research.
Among the two mechanisms of action, the PD-1 inhibitors were estimated to
contribute 97.2% to the global PD-1 and PD-L1 inhibitors market in 2016.
However, the approval of Tecentriq and expected approval of durvalumab and
avelumab during forecast period will significantly increase PD-L1 inhibitors
revenue contribution to the global market.
Some of the key players operating in the global market include Merck & Co.,
Inc., Bristol-Myers Squibb Company, AstraZeneca plc and others.

PD-1 & PD-L1 Inhibitors

Download report sample at:




For information regarding permissions and other queries

Kindly write to:


US/Canada Toll-Free: 1-888-778-7886


Related documents

pd 1 pd l1 inhibitors
global image sensors market
wearable sensors market
premature ejaculation treatment market
animal pharmaceuticals market
smart light fixture and control market size

Related keywords